Today, there are nearly 250 companies worldwide that are developing stem cell products for therapeutic use in humans to address a diverse range of chronic and acute conditions.
Currently, MSCs and hematopoietic stem cells are the most commonly used stem cell types. However, induced pluripotent stem cells (iPSCs) are also gaining traction, with dozens of companies now forging the path toward
iPSC-derived cellular therapeutics. Other stem cell types, such as neural stem cells and embryonic stem cells, are being used more selectively.
Of course, stem cell-derived exosomes have rapidly expanded their therapeutic applications in recent years too.
Recently, BioInformant launched a comprehensive database that identifies all known market competitors who are developing stem cell therapeutics for use in human patients.
Please note that it is a database of companies which are developing stem cell therapies through formal regulatory channels — such as the U.S. FDA, European Medicines Agency (EMA), Chinese NMPA, Japanese PMDA, etc.
Because this database has been highly requested by our clients and partners, we are confident you will find it to be invaluable too.
Through this Friday only, you can claim this database for 50% off:
Remember to act fast, because this offer expires soon!
Be Great,
The BioInformant Team
_________________________
Related (Suggested) Products:
_________________________
